Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cholestaway cholesterol binding, elimination claims prohibited under FTC settlement.

This article was originally published in The Tan Sheet

Executive Summary

CHOLESTAWAY CHOLESTEROL BINDING CLAIMS SUBJECT TO FTC SETTLEMENT with the product's marketer, Bogdana Corp., and its principles, Joseph and Bogda Gruber, released by the Federal Trade Commission May 12. Ad claims at issue in the case include statements that Cholestaway prevents fat from being absorbed and "does the same thing with cholesterol. It combines with it. One molecule of Cholestaway will bind two molecules of fat or two molecules of cholesterol." Cholestaway causes fat to "go right through you," the ad says, claiming fat in the diet "would actually become part of the stools and it would be eliminated." Cholestaway consists of wafers said to contain calcium and magnesium.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel